A neurological disorder is any disorder of the nervous system. Structural, biochemical or electrical abnormalities in the brain, spinal cord or other nerves can result in a range of symptoms. Examples of symptoms include paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain and altered levels of consciousness. There are many recognized neurological disorders, some relatively common, but many rare.
The early diagnosis of neurodegenerative indications is difficult because of their complex nature, fast progression, and lack of effective diagnostic processes. This has encouraged researchers to focus on the development of novel biomarkers that can accurately detect neurodegenerative indications.

Market Analysis and Insights: Global Neurologic Disorders Therapeutics Market
The global Neurologic Disorders Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurologic Disorders Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurologic Disorders Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurologic Disorders Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurologic Disorders Therapeutics market.

Global Neurologic Disorders Therapeutics Scope and Market Size
Neurologic Disorders Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurologic Disorders Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Central Nervous System (CNS)
Peripheral Nervous System (PNS)

Segment by Application
Paralysis
Muscle Weakness
Poor Coordination
Loss of Sensation
Seizures
Confusion
Pain and Altered Levels of Consciousness

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Biogen Inc.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services Inc.
Novartis AG
Pfizer Inc.